Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD.

BACKGROUND Drugs available for treating attention-deficit hyperactivity disorder (ADHD) are mainly selective norepinephrine (sNRIs) and dual norepinephrine-dopamine (NDRIs) reuptake inhibitors. The major problem of sNRIs lines in their delayed onset of action and partial- or non-responses, which makes NDRIs distinguished in drug efficacy. Understanding of the differential binding modes of these 2 types of drugs to their corresponding targets can give great insights into the discovery of privileged drug-like scaffolds with improved efficacy. So far, no such study has been carried out. METHODS A combinatorial computational strategy, integrating homology modeling, molecular docking, molecular dynamics (MD) and binding free energy calculation, was employed to analyze the binding modes of 8 clinically important ADHD drugs in their targets. RESULTS Binding modes of 2 types of ADHD drugs (sNRIs and NDRIs) in their targets was identified for the first time by MD simulation, and 15 hot spot residues were discovered as crucial for NDRIs' binding in hNET and hDAT. Comparing to sNRIs, a clear reduction in the hydrophobic property of NDRIs' one functional group was observed, and the depth of drugs' aromatic ring stretched into the pocket of both targets was further identified as key contributors to drugs' selectivity. CONCLUSIONS The hydrophobic property of NDRI ADHD drugs' one functional group contributes to their selectivity when bind hNET and hDAT. GENERAL SIGNIFICANCE These results provide insights into NDRI ADHD drugs' binding mechanisms, which could be utilized as structural blueprints for assessing and discovering more efficacious drugs for ADHD therapy.

[1]  M. Reith,et al.  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template. , 2015, Bioorganic & medicinal chemistry.

[2]  J. Buitelaar,et al.  Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. , 2013, Journal of child psychology and psychiatry, and allied disciplines.

[3]  M. Rosales-Hernández,et al.  Current Tools and Methods in Molecular Dynamics (MD) Simulations for Drug Design. , 2016, Current medicinal chemistry.

[4]  S. Sinning,et al.  Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters. , 2012, ACS chemical neuroscience.

[5]  Sunhwan Jo,et al.  CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..

[6]  M. Reith,et al.  The Atypical Stimulant and Nootropic Modafinil Interacts with the Dopamine Transporter in a Different Manner than Classical Cocaine-Like Inhibitors , 2011, PloS one.

[7]  J. Enders,et al.  Improved Chiral Separation of Methamphetamine Enantiomers Using CSP-LC-MS-MS. , 2016, Journal of analytical toxicology.

[8]  Feng Zhu,et al.  Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks , 2016, BioMed research international.

[9]  E. Gouaux,et al.  Neurotransmitter and psychostimulant recognition by the dopamine transporter , 2015, Nature.

[10]  B. Kirtman,et al.  Efficient vector potential method for calculating electronic and nuclear response of infinite periodic systems to finite electric fields. , 2007, The Journal of chemical physics.

[11]  L. Briars,et al.  A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder. , 2016, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[12]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[13]  Cheng Zhang,et al.  Nature's contribution to today's pharmacopeia , 2014, Nature Biotechnology.

[14]  Philip C Biggin,et al.  Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations , 2016, Journal of the American Chemical Society.

[15]  S. Sinning,et al.  Comparative modeling of the human monoamine transporters: similarities in substrate binding. , 2013, ACS chemical neuroscience.

[16]  M. Rutkowski,et al.  Phosphorylation of acyclonucleosides by nucleoside phosphotransferase from higher plants and bacteria. , 1991, Acta biochimica Polonica.

[17]  Weiwei Xue,et al.  The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective , 2016, PloS one.

[18]  A. S. Mackenzie MOBILITY OF MEDICAL MANPOWER , 1976, The Lancet.

[19]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[20]  H. E. Rosvold,et al.  Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. , 1979, Science.

[21]  P A Kollman,et al.  Structure and thermodynamics of RNA-protein binding: using molecular dynamics and free energy analyses to calculate the free energies of binding and conformational change. , 2000, Journal of molecular biology.

[22]  B. Schiøtt,et al.  Identification of a common binding mode for imaging agents to amyloid fibrils from molecular dynamics simulations. , 2013, Journal of the American Chemical Society.

[23]  C. Goldberger,et al.  Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder , 2015, Current medical research and opinion.

[24]  A. Sandelin,et al.  Interaction of Antidepressants with the Serotonin and Norepinephrine Transporters , 2012, The Journal of Biological Chemistry.

[25]  Feng Zhu,et al.  Differentiating Physicochemical Properties between Addictive and Nonaddictive ADHD Drugs Revealed by Molecular Dynamics Simulation Studies. , 2017, ACS chemical neuroscience.

[26]  Youyong Li,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. , 2013, The journal of physical chemistry. B.

[27]  Feng Xu,et al.  Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs. , 2015, Pharmacological research.

[28]  F. Castellanos,et al.  Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes , 2002, Nature Reviews Neuroscience.

[29]  R. Freyberg,et al.  Mechanisms of amphetamine action illuminated through optical monitoring of dopamine synaptic vesicles in Drosophila brain , 2016, Nature Communications.

[30]  J. Bibb,et al.  Attention-Deficit/Hyperactivity Phenotype in Mice Lacking the Cyclin-Dependent Kinase 5 Cofactor p35 , 2010, Biological Psychiatry.

[31]  Feng Zhu,et al.  Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study , 2016, Scientific Reports.

[32]  Feng Zhu,et al.  Performance Evaluation and Online Realization of Data-driven Normalization Methods Used in LC/MS based Untargeted Metabolomics Analysis , 2016, Scientific Reports.

[33]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[34]  P. Wakeley,et al.  Synthesis , 2013, The Role of Animals in Emerging Viral Diseases.

[35]  A. Narkpongphun,et al.  Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials , 2015, Drug design, development and therapy.

[36]  M. Liechti,et al.  Pharmacological characterization of designer cathinones in vitro , 2013, British journal of pharmacology.

[37]  Bo Li,et al.  NOREVA: normalization and evaluation of MS-based metabolomics data , 2017, Nucleic Acids Res..

[38]  Gábor J. Székely,et al.  Hierarchical Clustering via Joint Between-Within Distances: Extending Ward's Minimum Variance Method , 2005, J. Classif..

[39]  A. Altamura,et al.  The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects , 2011, CNS neuroscience & therapeutics.

[40]  Tingjun Hou,et al.  Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. , 2014, Physical chemistry chemical physics : PCCP.

[41]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2016, Current protocols in bioinformatics.

[42]  Tingjun Hou,et al.  P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape , 2014, PLoS Comput. Biol..

[43]  Sylvia Tippmann,et al.  Programming tools: Adventures with R , 2014, Nature.

[44]  Jahan B. Ghasemi,et al.  Computer‐aided drug design to explore cyclodextrin therapeutics and biomedical applications , 2017, Chemical biology & drug design.

[45]  Xiao Hua Ma,et al.  Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs , 2012, PloS one.

[46]  K. Perry,et al.  Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder , 2002, Neuropsychopharmacology.

[47]  Shuang Li,et al.  SVM-Prot 2016: A Web-Server for Machine Learning Prediction of Protein Functional Families from Sequence Irrespective of Similarity , 2016, PloS one.

[48]  Dan Li,et al.  Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies. , 2016, Physical chemistry chemical physics : PCCP.

[49]  Eric Gouaux,et al.  X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine , 2015, Nature Structural &Molecular Biology.

[50]  R. Blakely,et al.  Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.

[51]  Jacob Andersen,et al.  Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter , 2015, Scientific Reports.

[52]  Märtha Sund-Levander,et al.  Assessment of body temperature measurement options. , 2013, British journal of nursing.

[53]  L. Guo,et al.  Construction and structural modeling of a single-chain Fv-asparaginase fusion protein resistant to proteolysis. , 2000, Biotechnology and bioengineering.

[54]  B. Tidor,et al.  Rational Approaches to Improving Selectivity in Drug Design , 2012, Journal of medicinal chemistry.

[55]  B. Ploeger,et al.  Estimation of binding rate constants using a simultaneous mixed‐effects method: application to monoamine transporter reuptake inhibitor reboxetine , 2010, British journal of pharmacology.

[56]  Peer Bork,et al.  Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation , 2007, Bioinform..

[57]  B. Schiøtt,et al.  Ligand Induced Conformational Changes of the Human Serotonin Transporter Revealed by Molecular Dynamics Simulations , 2013, PloS one.

[58]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[59]  A. Yan,et al.  Aurora-A kinase inhibitor scaffolds and binding modes. , 2011, Drug discovery today.

[60]  Feng Zhu,et al.  Identification of the inhibitory mechanism of FDA approved selective serotonin reuptake inhibitors: an insight from molecular dynamics simulation study. , 2016, Physical chemistry chemical physics : PCCP.

[61]  Sequence analysis and homology modeling of peroxidase from Medicago sativa , 2012, Bioinformation.

[62]  A. Arnsten,et al.  Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions , 2004, Biological Psychiatry.

[63]  M. Reith,et al.  Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate‐binding sites in a single transporter , 2010, Journal of neurochemistry.

[64]  Jia Zhou Norepinephrine transporter inhibitors and their therapeutic potential. , 2004, Drugs of the future.

[65]  Martti T Tammi,et al.  What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets , 2009, Journal of Pharmacology and Experimental Therapeutics.

[66]  R. Lukas,et al.  Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. , 2009, Journal of medicinal chemistry.

[67]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[68]  Akbar Nayeem,et al.  A comparative study of available software for high‐accuracy homology modeling: From sequence alignments to structural models , 2006, Protein science : a publication of the Protein Society.

[69]  Weiliang Zhu,et al.  Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation , 2015, Scientific Reports.

[70]  Jörg Weiser,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999, J. Comput. Chem..

[71]  Tingjun Hou,et al.  Assessing the Performance of the MM/PBSA and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations Based on Molecular Dynamics Simulations , 2011, J. Chem. Inf. Model..

[72]  Lin Shi,et al.  Large-scale untargeted LC-MS metabolomics data correction using between-batch feature alignment and cluster-based within-batch signal intensity drift correction , 2016, Metabolomics.

[73]  M. Frank,et al.  From reinforcement learning models to psychiatric and neurological disorders , 2011, Nature Neuroscience.

[74]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[75]  C. Kilts,et al.  Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter. , 2009, Journal of medicinal chemistry.

[76]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[77]  Lu Huang,et al.  Update of TTD: Therapeutic Target Database , 2009, Nucleic Acids Res..

[78]  Tingjun Hou,et al.  Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches , 2013, J. Chem. Inf. Model..

[79]  N. Volkow,et al.  The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. , 2014, JAMA psychiatry.

[80]  F. Castellanos,et al.  Childhood Attention-Deficit/Hyperactivity Disorder and Homelessness: A 33-Year Follow-Up Study. , 2016, Journal of the American Academy of Child and Adolescent Psychiatry.

[81]  Dan Li,et al.  Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking. , 2016, Physical chemistry chemical physics : PCCP.

[82]  P. Kollman,et al.  Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .

[83]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[84]  Feng Zhu,et al.  Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters , 2017 .

[85]  Lin Tao,et al.  Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting , 2011, Proceedings of the National Academy of Sciences.

[86]  B Xie,et al.  Trends in the exploration of anticancer targets and strategies in enhancing the efficacy of drug targeting. , 2008, Current molecular pharmacology.

[87]  Kyeong-Man Kim,et al.  Exploration of substituted arylpiperazine-tetrazoles as promising dual norepinephrine and dopamine reuptake inhibitors. , 2016, Bioorganic & medicinal chemistry.

[88]  Benjamin D. Madej,et al.  Lipid14: The Amber Lipid Force Field , 2014, Journal of chemical theory and computation.

[89]  K. Patrick,et al.  Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity , 2007, Behavioural pharmacology.

[90]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[91]  C. Vasavi,et al.  Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations. , 2017, Journal of molecular graphics & modelling.

[92]  Ying Yang,et al.  Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with p38α MAP Kinase , 2011, J. Chem. Inf. Model..

[93]  F. Tarazi,et al.  Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB‐1020: Implications for treatment of attention‐deficit hyperactivity disorder , 2012, Synapse.

[94]  G. Madhavi Sastry,et al.  Homology modeling of membrane proteins: A critical assessment , 2006, Comput. Biol. Chem..

[95]  S. Faraone,et al.  A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder , 2005, Biological Psychiatry.

[96]  Feng Xu,et al.  Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information , 2015, Nucleic Acids Res..

[97]  H. Sitte,et al.  Probing the Selectivity of Monoamine Transporter Substrates by Means of Molecular Modeling , 2013, Molecular informatics.

[98]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[99]  H. Navarro,et al.  Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. , 2009, Journal of medicinal chemistry.

[100]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2007, Current protocols in protein science.

[101]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[102]  Stefan Johansson,et al.  Multicenter Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD Suggests Differential Involvement of the Gene in Childhood and Persistent ADHD , 2010, Neuropsychopharmacology.

[103]  Feng Zhu,et al.  Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods. , 2015, Bio-medical materials and engineering.

[104]  Zhen Yan,et al.  Methylphenidate Exerts Dose-Dependent Effects on Glutamate Receptors and Behaviors , 2014, Biological Psychiatry.